Back to Journals Drug Design, Development and Therapy Volume 19 Semaglutide Therapy and Accelerated Sarcopenia in Older Adults with Type 2 Diabetes: A 24-Month Retrospective Cohort Study Received 1 April 2025 Accepted for publication 25 June 2025 Published 3 July 2025 Volume 2025:19 Pages 56455652 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Tuo Deng Qingjuan Ren, Lei Zhi, Hongfang Liu Department of Geriatrics, Shijiazhuang Peoples Hospital, Shijiazhuang, Hebei, Peoples Republic of China Correspondence: Qingjuan Ren, Department of Geriatrics, Shijiazhuang Peoples Hospital, Shijiazhuang, Hebei, Peoples Republic of China, Email [email protected] Purpose: This study aimed to investigate changes in muscle mass and strength among older adults with type 2 diabetes who were treated with Semaglutide
Htet Wai Moe, MBBS, MD, PhD-Pharmacology Non-arteritic anterior ischemic optic neuropathy (NAION) is a rare but serious condition caused by reduced blood flow to the optic nerve
B.AveryC
Mt s bnh nhn c th s dng thuc trong vi thng di s gim st ca bc s ng thi thc hin nhng thay i v li sng
A recent study by Professor Andrew Hill et al i suggests that finished forms of semaglutide pens can be sold to patients for anything between $2.50-$12 per month, but this underestimates a large number of costs associated with sourcing from diverse geographies, as well as costs during the market access process
